Chemcon Speciality Chemicals Limited – Investor Presentation Summary
Key Operational Highlights
- Reported sales volume data shows FY22: 10,076 MT, FY23: 10,975 MT, FY24: 12,131 MT, FY25: 10,213 MT, FY26: 9,991 MT
- Export contribution was 37% in FY26
- Key drivers: Higher volumes and better realizations across key products in both Organic and Inorganic Chemicals segments
- New products Bromobenzene and 2-Bromo saw encouraging response from pharmaceutical, agrochemical, aromatic chemical industries
Segment-wise Performance
- Organic Chemicals segment (HMDS, CMIC, Bromobenzene, 2-Bromo) delivered improved performance
- Inorganic Chemicals segment (Bromides) delivered improved performance
- Explanation: Performance improvement driven by higher volumes and better realizations across key products
Financial Highlights
Revenue: Rs. 240.0 crore (FY26)
EBITDA: Rs. 30.2 crore (FY26)
PAT: Rs. 23.6 crore (FY26)
EPS: Rs. 6.44 (FY26)
Margins: EBITDA Margin 12.6% (FY26), PAT Margin 9.8% (FY26)
YoY comparison: Revenue growth 16% YoY (FY26 vs FY25), PAT decline -3% YoY (FY26 vs FY25)
Drivers of financial performance: Higher volumes and better realizations across key products
Key Risks: Subdued demand conditions, pricing pressure across key products, geopolitical uncertainties, volatility in crude oil prices
Q4 FY26 Financial Highlights:
Revenue: Rs. 75.4 crore (37% YoY growth, 32% QoQ growth)
EBITDA: Rs. 8.9 crore (54% YoY growth, 34% QoQ growth)
PAT: Rs. 6.4 crore (61% YoY growth, 25% QoQ growth)
EBITDA Margin: 11.8% (Q4 FY26)
PAT Margin: 8.4% (Q4 FY26)
Geographical Revenue Split
Domestic vs Export Revenue: Export contribution 37% (FY26)
Balance Sheet Snapshot
Net Debt/Equity: Not explicitly specified
Reserves: Not explicitly specified
Current Assets: Rs. 346.0 crore (Mar-26)
Current Liabilities: Rs. 78.5 crore (Mar-26)
Property, Plant and Equipment: Rs. 194.6 crore (Mar-26)
Capital Work in Progress: Rs. 20.9 crore (Mar-26)
Total Assets: Rs. 568.0 crore (Mar-26)
Total Equity: Rs. 483.1 crore (Mar-26)
Financial Health Insights: Strong cash position with bank balances of Rs. 178.2 crore (Mar-26)
Capex & Cash Flow Health
Capital Expenditure: Not explicitly specified for future periods
Free Cash Flow: Not explicitly specified
Operating Cash Flow: Net Cash from Operating Activities Rs. 41.5 crore (FY26)
Net Debt Movement: Not explicitly specified
Investment Rationale: Capacity expansion through P10 and P11 units
Strategic & R&D Initiatives
Investments in Innovation: Acquisition of Shivam Petrochem Industries for ₹36 crore through slump sale
Expected impact on growth: Acquired business expected to begin contributing to revenues in coming quarters
Strategic Rationale: Strengthens presence across bulk drugs, chemical intermediates, solvents, and specialty chemicals; adds technical know-how, product capabilities, and experienced talent; provides access to new markets and customers
Products from acquisition: Trityl Chloride (TTC), 1-[(2-Chlorophenyl)(Diphenyl)Methyl] 1H-imidazole, Para Toluene Sulfonyl Chloride (PTSCL), 2-Chlorotrityl Chloride (2CTC), Toluenesulfonylmethyl isocyanide (TosMIC), 2-Acetylthiophene, Thiophene-2-acetyl Chloride, Thiophene-2-carboxaldehyde, Pyridine-4-carbaldehyde
Manufacturing Capacity Expansion:
- Successfully commissioned P10 and P11 units
- Organic Chemicals installed capacity: 11,400 MTPA
- Inorganic Bromides installed capacity: 15,000 MTPA
- Located at Manjusar near Vadodara, Gujarat: 9 Operational Units, 2 Proposed Expansion Plants under process, In-House R&D Laboratory, 6 Owned Warehouses
Industry Trends & Business Environment
Macro/Industry Trends: Subdued demand conditions, pricing pressure across key products, geopolitical uncertainties, volatility in crude oil prices
Impact on Company: Overall performance during FY26 was partly affected by these factors
Management Commentary & Growth Outlook
Strategic Outlook: "We remain optimistic in our strategy to diversify and broaden our product offerings, while foreseeing healthy growth opportunities going forward" - Mr. Kamal Aggarwal, Chairman & Managing Director
FY Guidance: Not explicitly specified
Market Share Targets: Not explicitly specified
Risks and Opportunities: Not explicitly specified beyond mentioned industry challenges